期刊
MOLECULAR THERAPY-ONCOLYTICS
卷 14, 期 -, 页码 266-278出版社
CELL PRESS
DOI: 10.1016/j.omto.2019.07.003
关键词
-
资金
- BC Lung Association
- Providence Health Care Research Institute (PHCRI)
- Vancouver Coastal Health Research Institute (VCHRI) Innovation and Translational Research Award
- Natural Sciences and Engineering Research Council [RGPIN-2016-03811]
- Canadian Institutes of Health Research [PJT-148725]
- Terry Fox Research Institute
- BC Cancer Foundation
- University of British Columbia
- Michael Smith Foundation for Health Research
- Canadian Institutes of Health Research
- International Association for the Study of Lung Cancer Young Investigator Awards
KRAS mutant (KRAS(mut)) lung adenocarcinoma is a refractory cancer without available targeted therapy. The current study explored the possibility to develop coxsackievirus type B3 (CVB3) as an oncolytic agent for the treatment of KRAS(mut) lung adenocarcinoma. In cultured cells, we discovered that CVB3 selectively infects and lyses KRAS(mut) lung adenocarcinoma cells (A549, H2030, and H23), while sparing normal lung epithelial cells (primary, BEAS2B, HPL1D, and 1HAEo) and EGFR(mut) lung adenocarcinoma cells (HCC4006, PC9, H3255, and H1975). Using stable cells expressing a single driver mutation of either KRAS(G12V) or EGFR(L858R) in normal lung epithelial cells (HPL1D), we further showed that CVB3 specifically kills HPL1D-KRAS(G12V) cells with minimal harm to HPL1D-EGFR(L858R) and control cells. Mechanistically, we demonstrated that aberrant activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and compromised type I interferon immune response in KRAS(mut) lung adenocarcinoma cells serve as key factors contributing to the sensitivity to CVB3-induced cytotoxicity. Lastly, we conducted in vivo xenograft studies using two immunocompromised mouse models. Our results revealed that intratumoral injection of CVB3 results in a marked tumor regression of KRAS(mut) lung adenocarcinoma in both non-obese diabetic (NOD) severe combined immunodeficiency (SCID) gamma (NSG) and NOD-SCID xenograft models. Together, our findings suggest that CVB3 is an excellent candidate to be further developed as a targeted therapy for KRAS(mut) lung adenocarcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据